ArticleHuman vaccines & immunotherapeutics2018
Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination.
Article in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial.PLoS neglected tropical diseases · 2023Trial
- A distinct E dimer epitope underlies selective recognition by a protective human West Nile virus antibody.EMBO reports · 2026Article
- Adenoviral Vectors Expressing Optimized preM/E Genes of WNV Deliver Long-Term Protection Against Lethal West Nile Virus Challenge.Vaccines · 2025Article
- Detection of Bagaza Virus in Europe: A Scoping Review.Veterinary sciences · 2025Review
- Accelerating targeted mosquito control efforts through mobile West Nile virus detection.Parasites & vectors · 2024Article
- Trends in ELISA-Based Flavivirus IgG Serosurveys: A Systematic Review.Tropical medicine and infectious disease · 2023Review
- Immunization with different recombinant West Nile virus envelope proteins induces varying levels of serological cross-reactivity and protection from infection.Frontiers in cellular and infection microbiology · 2023Article
- European College of Equine Internal Medicine consensus statement on equine flaviviridae infections in Europe.Journal of veterinary internal medicine · 2022Article
- Epidemiological Trends of Trans-Boundary Tick-Borne Encephalitis in Europe, 2000-2019.Pathogens (Basel, Switzerland) · 2022Review
- Challenges for Vaccinologists in the First Half of the Twenty-First Century.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Determinants in Nonstructural Protein 4A of Dengue Virus Required for RNA Replication and Replication Organelle Biogenesis.Journal of virology · 2021Article
- Targeting the protease of West Nile virus.RSC medicinal chemistry · 2021Review
- TBEV Subtyping in Terms of Genetic Distance.Viruses · 2020Article
- Virus-Like Particle Systems for Vaccine Development against Viruses in the Flaviviridae Family.Vaccines · 2019Review
- Article
- West Nile virus vaccines - current situation and future directions.Human vaccines & immunotherapeutics · 2019Review
- Equine viral encephalitis: prevalence, impact, and management strategies.Veterinary medicine (Auckland, N.Z.) · 2019Article
- Review
- Production of complex viral glycoproteins in plants as vaccine immunogens.Plant biotechnology journal · 2018Review
- Integrated analysis of human-animal-vector surveillance: West Nile virus infections in Austria, 2015-2016.Emerging microbes & infections · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tick-borne encephalitis and West Nile fever are endemic flavivirus diseases in Europe. Climate change, virus evolution, and social factors may increase the risk of these flavivirus infections and may lead to the emergence of other flaviviruses in Europe that are endemic in (sub)tropical regions of the world. Control of the spread of flaviviruses is very difficult considering the cycling of flaviviruses between arthropod vectors and animal reservoir hosts. The increasing threat of flavivirus infections emphasizes the necessity of a sustainable vector surveillance system, an active animal health surveillance system and an adequate human surveillance system for early detection of flavivirus infections. Vaccination is the most important approach to prevent flavivirus infections. Effective inactivated whole virus vaccines against tick-borne encephalitis (TBE) infection are available. Implementation of TBE vaccination based on favorable cost-effectiveness estimates per region and per target group can reduce the disease burden of TBE infection. At present, several West Nile virus (WNV) vaccine candidates are in various stages of clinical development. A major challenge for WNV vaccine candidates is to demonstrate efficacy, because of the sporadic nature of unpredictable WNV outbreaks. Universal WNV vaccination is unlikely to be cost-effective, vaccination of high-risk groups will be most appropriate to protect against WNV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.